Insilico Medicine expects H1 2026 net profit of USD 33.5 million-USD 39.5 million

• Insilico Medicine flagged a swing to profit in H1 2026, based on unaudited management accounts.
• Revenue expected at USD 102.5 million to USD 106.5 million, up 272.7% to 287.3% from USD 27.5 million a year earlier.
• Net profit forecast at USD 33.5 million to USD 39.5 million, versus a USD 19.2 million net loss in H1 2025.
• Adjusted non-IFRS net profit seen at USD 45.5 million to USD 51.5 million, compared with a USD 15.4 million adjusted loss.
• Outlook driven by higher out-licensing and collaboration revenue, supported by improved operating efficiency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260709-12238635), on July 09, 2026, and is solely responsible for the information contained therein.